Q-omics provides the consensus-scored NOLC1 profile across patient tissues and cancer cell-line models. NOLC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NOLC1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, NOLC1 protein abundance shows 25,594 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where NOLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOLC1 survival associations across molecular data types. NOLC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOLC1 RNA expression–survival associations across cancer types. High NOLC1 expression shows unfavorable associations in KIRP, ACC, LUAD, CESC, UVM and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NOLC1 RNA expression.
This table summarizes NOLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NOLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOLC1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, STAD, LIHC and LUAD. The COAD box plot shows higher NOLC1 RNA expression in tumor versus normal tissue (log2 FC = +1.272, t-test p < 0.001).
This table shows molecular features associated with NOLC1 in patient tissues and cancer cell lines. In patient samples, NOLC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
